As one of the world’s leading specialty biopharmaceutical companies, Shire
has emerged as a company fully focused on a single purpose: to enable people
with life-altering conditions to lead better lives.
Through our Shire Human Genetic Therapies (HGT) business, we pursue
opportunities on behalf of patients and families facing such rare diseases as
Fabry disease, Hunter syndrome, Gaucher disease, hereditary angioedema, and
metachromatic leukodystrophy—patients whose very lives often hinge on the
discovery and delivery of extraordinary medicines. Through our specialty
pharmaceutical business, meanwhile, we develop and distribute an innovative
portfolio of treatments for patients with ADHD, ulcerative colitis, and
end-stage renal disease. Our commitment throughout is on symptomatic diseases,
treated by specialist physicians. We take the risks we need to take so that we
might change lives for the discernible better.
Strategic partnerships have fueled Shire’s rapid growth—acquisitions and
mergers designed to fortify development as well as marketed portfolios. In
the twenty plus years of Shire’s short history, the majority of our new
products have joined our portfolio of existing medicines via an acquisition
or partnership. The only exception being our HGT business, where development
of enzyme replacement therapies from early phases is lower risk than the
discovery of small molecules and we have an active in-house early research
capability. Today nearly two dozen projects are in full development in
Shire’s HGT and Specialty Pharma pipeline and 30 per cent of our revenue is
derived from products launched within the last two years.
At the same time, Shire has systematically extended its global reach by
building operations in countries as far-flung as Australia and Argentina,
Mexico and Japan, and Russia and Thailand. By offering a range of essential
medicines to patients all over the world, Shire has gained a reputation as a
company that delivers on the promises it makes.
It is our mission by 2015 to have 50 per cent of our sales come from outside of
the traditional US and European markets.
We also care, at Shire, about the communities in which we live and
work—about who we are and the legacy we leave behind. Through countless
Corporate Responsibility initiatives, we’re making a difference by
supporting programs ranging from the education of young scientists and the
beautifying of natural landscapes to the reduction of CO2 emissions and the
development of a green-oriented employee family.
At Shire we are perpetually planning for the future. We’re exploring new
markets. We’re conversing with thought leaders. We’re listening to patients and
families, to innovators and inventors. We’re asking ourselves what more we can
do to make this world a healthier place and in doing so, we’re mindful of our
overall cultural ethos; to be as brave as the people we help.
To learn more, please visit the Shire corporate website at